Jessica Thueringer

@DoctorLix So sorry! We just finished 14 day quarantines for my 2 school agers who both had exposures the 1st day of school, at different schools...

And…we’re on quarantine.

On behalf of the entire #COVaRiPAD team, we are thrilled to announce our preprint reporting humoral responses after BOTH doses of mRNA-based SARS-CoV-2 vax in 133 pts w/ chronic inflammatory diseases (CID) and 53 immunocompetent controls: medrxiv.org/content/10.110…. 1/

The ACR has developed new guidance for #rheumatology providers on the use of the #COVID19 vaccines for patients with rheumatic & musculoskeletal diseases. Details → acr.tw/3tJ2KF2

Bedside to Bench: Disease Taxonomy via Specific Targeting #ACR20 #ACRambassador

Great talk #ACR20 @anisha_dua re:monitoring in GCA/TAK Remember different distributions in GCA/TAK Slick summary slides with pros/cons of each modality I find myself picking based on clinical context, suspected involvement/extent, and availability #ACRambassador

What a fantastic start to #ACR20 !! Congratulations @ACRheum The best 30 min ever spent reviewing 1 year worth of clinical research!! Superb talk by @JYazdanyMD 👌

TODAY: ACR issued recommendations for rheumatologists treating rheumatic diseases during #COVID19 pandemic, per guidance by task force of rheumatologists & ID docs, approved by ACR board. "Living document" will change/add more as data emerge. See below 1/7 rheumatology.org/Portals/0/File…

Primary care providers - take a look at these new gout guidelines. They're very straightforward, and your patients will do much better than if you follow the ACP guidelines. #ACR19

Looks like giving methotrexate with pegloticase means most can complete their infusion course in uncontrolled #gout. Reduced reactions. MTX to the rescue! #ACR19 @RheumNow Abs 1236

Relapsing Polychondritis: speaker’s recommendations #ACR19 @rheumnow 4M086

#acr19 Final recs from Rohit Aggarwal on cancer screening in myositis.

#acr19 @rheumnow Draft ACR guidelines for Takayasu: 1. Use noninvasive imaging over cath based imaging 2. Use high dose GCs 3. use DMARD with GCs (MTX, AZP, LEF, MMF) 4. With refractory dz, add TNFi (NOT TCZ!) 5. Monitor dz q3-12 months if in remission

NEW Guidelines for the Management of Polyarteritis Nodosa (PAN) at #ACR19 (in one table!) 1. Go big w/biopsy 2. Cytoxan>Rituxan for severe dx 3. Follow cytoxan with GC sparing agent; stop after 18mos in remission 4. TNF for pts with DADA2 @RheumNow

NEW Guidelines for the Management of GCA from #ACR19 in one table 1. Recommend TAB over TA U/S for dx GCA 2. Pts should receive TCZ upfront 3. Don't treat asymptomatic CRP, monitor patients closely Overall in line with my practice, though I'm pro TA U/S @RheumNow

Here’s the handout we created to help rheumatologists guide pregnancy planning for women with lupus. lupuspregnancy.org/preparing-for-… @LupusPregnancy. #acr19

#ACR19 #YearInReview by Dr. Susan Manzi For PsA and PsO: 🔵SPIRT-H2H: head to head trial of ixekizumab vs adalimumab (IL17i superior) in PsA ncbi.nlm.nih.gov/pubmed/31563894 🔵Ustekinumab vs TNFi on CVE and AFib in PsA - no sig difference seen ncbi.nlm.nih.gov/pubmed/30916734

Dr Y Yazici @ACR19 @rheumnow Behcet’s Rx: 1. Colchicine 2.AZP prevents eye dz from becoming bilateral and helps with ulcers and arthritis (no diff for CNS dz or thrombosis) 3.TNFi (min 2 years) 4.Ustekinumab (small pilot study) “IL1 inh does NOT work in Behcet‘s”

NEW ANCA Associated Vasculitis Guidelines - discussed at #ACR19 1. Rituxan > cytoxan 2. Reduced steroid regimen! 3. Rec against PLEX 4. Rec FOR scheduled RTX over ANCA+B cell guided 5. MTX for limited dx Well done everyone - very reasonable and evidence based! @RheumNow

NEW Draft Guidelines for EGPA presented at #ACR19 @RheumNow 1. TTE and FFS to guide tx 2. GC plus cytoxan or rituxan for active/severe dx 3. Imuran/MMF/MTX for maintenance after severe dx 4. Mepo for non-severe over csDMARDs Larger role for RTX than expected, overall reasonable